Antiemetics Market Expected to Reach $4.1 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Antiemetics Market," The antiemetics market was valued at $2.3 billion in 2021, and is estimated to reach $4.1 billion by 2031, growing at a CAGR of 6.1% from 2022 to 2031.

Antiemetic drugs such as aprepitant, dexamethasone, dolasetron, granisetron, ondansetron, palonosetron, prochlorperazine, and rolapitant are used to prevent nausea and vomiting conditions in patients. Nausea and vomiting may be caused due to various ailments such as motion sickness, morning sickness during pregnancy, severe cases of stomach flu, and other infections. In addition, nausea and vomiting are common parts of chemotherapy treatment, which leads to a rise in demand for antiemetic medications.

In addition, factors that drive the growth of the global antiemetics market include a rise in demand for antiemetics medications to treat emesis associated with chemotherapy and radiation therapy, advancements in the field of treatments, and investments in R&D activities by key market players. In addition, the rise in the prevalence of gastroenteritis and other gastric issues increases the need for antiemetic drugs, which are the upcoming antiemetics market trends.

Furthermore, the rise in the prevalence of vertigo is driving the growth of the market. Vertigo is a sensation of feeling off balance along with nausea and vomiting, headache and sweating. The causes of vertigo include vestibular neuritis or labyrinthitis, Meniere’s disease, and Benign paroxysmal positional vertigo (BPPV). However, vertigo is a condition and not a disorder, therefore most patients ignore the symptoms and causes of vertigo. Hence, vertigo conditions are rising globally, which also drives the antiemetics market.

Furthermore, the new product launches and product approvals by the public and private players will provide a lucrative opportunity for the market. For instance, in February 2020, Acacia Pharma received USFDA Approval for Barhemsys (amisulpride) for the treatment and prevention of postoperative nausea and vomiting (PONV). Moreover, a surge in the number of advancements in diagnosis and treatment further fuels the growth of the market. 

Furthermore, the antiemetics market has gained the interest of many pharmaceutical companies, owing to the surge in demand for the medications due to the rise in the patient pool in the regions such as Asia-Pacific and LAMEA.  

The global antiemetics market analysis is segmented on the basis of drug type, application, distribution channel, and region.

On the basis of drug type, the market is segregated into antihistamines, serotonin receptor antagonists, dopamine receptor antagonists, neurokinin receptor antagonists, anticholinergics, and others. The serotonin receptor antagonists segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to a rise in R&D activities related to the advanced manufacturing process of serotonin receptor antagonist products in the antiemetics sector and an increase in the prevalence of emesis-associated conditions.

Depending on the application, the antiemetics industry is segmented into chemotherapy, post-operative surgery, pregnancy and gastroenteritis, and others. The chemotherapy segment dominated the antiemetics market size in 2021. On the contrary, the post-operative surgery segment is expected to grow at the fastest CAGR during the forecast period, owing to the rise in the number of surgeries, which causes post-operative symptoms like nausea and vomiting.

By distribution channel, the market is categorized into retail pharmacies, hospital pharmacies, and online pharmacies. In 2021, the retail pharmacies segment held the largest share of the global antiemetics market size, mainly driven by the large number of patient visits to the retail pharmacies as they offer the precise drug according to status of disease of patient and easy accessibility of the facilities. On the other hand, the online pharmacies segment is expected to grow at the highest CAGR during the antiemetics market forecast, due to the digitalization around the globe.

North America acquired major of the antiemetics market share in 2021, owing to the presence of key players, rising government initiatives, well-developed healthcare infrastructure, and rising prevalence of health issues. However, Asia-Pacific is expected to register highest CAGR from 2022 to 2031, owing to the rapid changes in the environmental conditions and associated viral and bacterial disease which causes nausea and vomiting.

KEY FINDINGS OF THE STUDY

• On the basis of drug type, the serotonin receptor antagonists segment held the largest market share in 2021, and is expected to remain dominant during the forecast period.
• On the basis of application, the chemotherapy segment held the largest antiemetics market share in 2021, whereas the post operative surgery segment is expected to remain dominant during the forecast period.
• On the distribution channel, the retail pharmacies segment held largest market share in 2021, whereas the online pharmacies is expected to grow at the fastest CAGR rate during the forecast period.
• Region wise, North America held the largest share of the antiemetics industry in the year 2021, whereas the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period.